Investment Thesis
Protara is a pre-revenue biopharmaceutical company generating only $178K in annual revenue while burning $56.5M in operating cash annually. With $49.7M in cash and minimal runway, the company faces near-term solvency risk absent successful drug development and capital raises.
Strengths
- Strong balance sheet with $196.4M stockholders equity and zero debt
- Excellent liquidity with 14.58x current ratio and $49.7M cash position
- No long-term debt obligations limiting financial flexibility
Risks
- Pre-revenue stage with only $178K revenue and 101.2% YoY decline
- Negative $56.5M operating cash flow with less than 1 year cash runway
- Entirely dependent on unproven drug development, clinical trial success, and FDA approval
Key Metrics to Watch
- Monthly cash burn rate and adjusted runway timeline
- Clinical trial progress and regulatory milestone achievements
- Capital raise activities and revenue-generating product development status
Financial Metrics
Revenue
178.0K
Net Income
-57.4M
EPS (Diluted)
$-1.34
Free Cash Flow
-56.5M
Total Assets
209.5M
Cash
49.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-36,263.5%
Net Margin
-32,269.1%
ROE
-29.2%
ROA
-27.4%
FCF Margin
-31,718.5%
Balance Sheet & Liquidity
Current Ratio
14.58x
Quick Ratio
14.58x
Debt/Equity
0.00x
Debt/Assets
6.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-17T03:00:22.592419 |
Data as of: 2025-12-31 |
Powered by Claude AI